Sign in
← Database
GHRH Analog

CJC-1295

Buy · Omnichems ↗Buy · Disguised Alpha ↗
Third-party suppliers · research use only · not an endorsement. Some links are affiliate links — purchases made through them may earn this site a commission.
Overview

Early human studies measured GH/IGF-1 elevation; not approved for general use.

How it works

CJC-1295 is a modified version of GHRH (the brain's growth-hormone-releasing signal). It comes in two forms, with or without a component called DAC, and the difference is mostly about how long it lasts.

On the pituitary it does the GHRH job — stimulating GH and IGF-1 while keeping the natural pulsing pattern, raising both the peaks and the troughs. The DAC version adds a chemical handle that binds albumin in the blood, stretching its half-life from minutes (the non-DAC form) to several days.

In the small early human study it produced sustained GH/IGF-1 increases and was reasonably tolerated, but the human data stop there — commercial development never advanced, and it remains a research compound rather than an approved drug.

Mechanism · Detailed Analysis
Molecular targetA modified GHRH(1-29) analogue at pituitary GHRH receptors; the DAC variant carries a maleimido group that binds albumin in vivo.
Signaling & downstream effectsSustained elevation of GH and IGF-1 while preserving pulsatility (it raises both pulse amplitude and trough).
PharmacokineticsThe DAC version extends half-life to days via albumin binding; the non-DAC version is short-acting.
CaveatsHuman data are limited to early PK/PD studies; commercial development ceased.
Published EvidenceLoading cited studies from PubMed…
Human Data ···

Searching the published record…

Animal ···

Searching the published record…

In Vitro ···

Searching the published record…

Educational aggregation of public literature. Not medical advice and not a recommendation to use any compound. Many compounds here are not approved for human use. Consult a licensed clinician.